vs
Side-by-side financial comparison of EASTERN CO (EML) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $55.3M, roughly 1.7× EASTERN CO). Vericel Corp runs the higher net margin — 25.0% vs 1.0%, a 24.0% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -22.4%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $3.1M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -0.6%).
EASTERN COEMLEarnings & Financial Report
China Eastern Airlines is a major airline in China, headquartered in Changning, Shanghai. It is one of the three major airlines in the country, along with Air China and China Southern Airlines.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
EML vs VCEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $55.3M | $92.9M |
| Net Profit | $578.9K | $23.2M |
| Gross Margin | 22.3% | 78.7% |
| Operating Margin | 3.1% | 24.1% |
| Net Margin | 1.0% | 25.0% |
| Revenue YoY | -22.4% | 23.3% |
| Net Profit YoY | 103.8% | 17.3% |
| EPS (diluted) | $0.10 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $92.9M | ||
| Q3 25 | $55.3M | $67.5M | ||
| Q2 25 | $70.2M | $63.2M | ||
| Q1 25 | $63.3M | $52.6M | ||
| Q4 24 | $64.3M | $75.4M | ||
| Q3 24 | $71.3M | $57.9M | ||
| Q2 24 | $72.6M | $52.7M | ||
| Q1 24 | $64.6M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $578.9K | $5.1M | ||
| Q2 25 | $3.4M | $-553.0K | ||
| Q1 25 | $1.9M | $-11.2M | ||
| Q4 24 | $1.3M | $19.8M | ||
| Q3 24 | $-15.3M | $-901.0K | ||
| Q2 24 | $3.5M | $-4.7M | ||
| Q1 24 | $1.9M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | 22.3% | 73.5% | ||
| Q2 25 | 23.3% | 73.7% | ||
| Q1 25 | 22.4% | 69.0% | ||
| Q4 24 | 23.6% | 77.6% | ||
| Q3 24 | 25.5% | 71.9% | ||
| Q2 24 | 25.4% | 69.5% | ||
| Q1 24 | 23.9% | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | 3.1% | 5.1% | ||
| Q2 25 | 4.5% | -3.2% | ||
| Q1 25 | 5.1% | -24.3% | ||
| Q4 24 | 6.1% | 24.5% | ||
| Q3 24 | 9.5% | -4.3% | ||
| Q2 24 | 8.3% | -11.5% | ||
| Q1 24 | 5.3% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | 1.0% | 7.5% | ||
| Q2 25 | 4.9% | -0.9% | ||
| Q1 25 | 3.1% | -21.4% | ||
| Q4 24 | 2.0% | 26.3% | ||
| Q3 24 | -21.5% | -1.6% | ||
| Q2 24 | 4.8% | -8.9% | ||
| Q1 24 | 3.0% | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | $0.10 | $0.10 | ||
| Q2 25 | $0.56 | $-0.01 | ||
| Q1 25 | $0.32 | $-0.23 | ||
| Q4 24 | $0.22 | $0.40 | ||
| Q3 24 | $-2.46 | $-0.02 | ||
| Q2 24 | $0.56 | $-0.10 | ||
| Q1 24 | $0.31 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.2M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $124.3M | $354.6M |
| Total Assets | $220.0M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $9.2M | $135.4M | ||
| Q2 25 | $9.1M | $116.9M | ||
| Q1 25 | $10.2M | $112.9M | ||
| Q4 24 | $16.1M | $116.2M | ||
| Q3 24 | $9.7M | $101.7M | ||
| Q2 24 | $2.0M | $102.5M | ||
| Q1 24 | $2.1M | $110.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $42.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $354.6M | ||
| Q3 25 | $124.3M | $321.9M | ||
| Q2 25 | $124.4M | $306.8M | ||
| Q1 25 | $121.0M | $295.5M | ||
| Q4 24 | $120.7M | $292.0M | ||
| Q3 24 | $119.2M | $257.5M | ||
| Q2 24 | $136.5M | $243.0M | ||
| Q1 24 | $134.5M | $233.9M |
| Q4 25 | — | $488.0M | ||
| Q3 25 | $220.0M | $453.3M | ||
| Q2 25 | $229.4M | $435.6M | ||
| Q1 25 | $232.3M | $424.6M | ||
| Q4 24 | $235.3M | $432.7M | ||
| Q3 24 | $244.2M | $390.4M | ||
| Q2 24 | $255.9M | $376.8M | ||
| Q1 24 | $253.9M | $356.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.1M | $15.0M |
| Free Cash FlowOCF − Capex | $3.1M | $12.8M |
| FCF MarginFCF / Revenue | 5.5% | 13.8% |
| Capex IntensityCapex / Revenue | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit | 5.38× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $12.3M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | $3.1M | $22.1M | ||
| Q2 25 | $3.8M | $8.2M | ||
| Q1 25 | $-1.8M | $6.6M | ||
| Q4 24 | $11.0M | $22.2M | ||
| Q3 24 | $-2.9M | $10.2M | ||
| Q2 24 | $8.4M | $18.5M | ||
| Q1 24 | $2.8M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | $3.1M | $19.5M | ||
| Q2 25 | $3.0M | $81.0K | ||
| Q1 25 | $-2.7M | $-7.6M | ||
| Q4 24 | $9.0M | $8.5M | ||
| Q3 24 | $-7.7M | $-9.2M | ||
| Q2 24 | $7.3M | $1.8M | ||
| Q1 24 | $1.1M | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | 5.5% | 28.8% | ||
| Q2 25 | 4.3% | 0.1% | ||
| Q1 25 | -4.3% | -14.5% | ||
| Q4 24 | 13.9% | 11.2% | ||
| Q3 24 | -10.8% | -15.9% | ||
| Q2 24 | 10.1% | 3.4% | ||
| Q1 24 | 1.7% | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 1.1% | 12.9% | ||
| Q1 25 | 1.3% | 27.0% | ||
| Q4 24 | 3.2% | 18.3% | ||
| Q3 24 | 6.7% | 33.5% | ||
| Q2 24 | 1.5% | 31.8% | ||
| Q1 24 | 2.6% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | 5.38× | 4.35× | ||
| Q2 25 | 1.09× | — | ||
| Q1 25 | -0.95× | — | ||
| Q4 24 | 8.41× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.40× | — | ||
| Q1 24 | 1.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EML
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
